160 related articles for article (PubMed ID: 15751035)
1. Epigenetic silencing of the imprinted gene ZAC by DNA methylation is an early event in the progression of human ovarian cancer.
Kamikihara T; Arima T; Kato K; Matsuda T; Kato H; Douchi T; Nagata Y; Nakao M; Wake N
Int J Cancer; 2005 Jul; 115(5):690-700. PubMed ID: 15751035
[TBL] [Abstract][Full Text] [Related]
2. Loss of expression of ZAC/PLAGL1 in diffuse large B-cell lymphoma is independent of promoter hypermethylation.
Valleley EM; Cordery SF; Carr IM; MacLennan KA; Bonthron DT
Genes Chromosomes Cancer; 2010 May; 49(5):480-6. PubMed ID: 20175198
[TBL] [Abstract][Full Text] [Related]
3. Alternative splicing of the imprinted candidate tumor suppressor gene ZAC regulates its antiproliferative and DNA binding activities.
Bilanges B; Varrault A; Mazumdar A; Pantaloni C; Hoffmann A; Bockaert J; Spengler D; Journot L
Oncogene; 2001 Mar; 20(10):1246-53. PubMed ID: 11313869
[TBL] [Abstract][Full Text] [Related]
4. Loss of expression of the candidate tumor suppressor gene ZAC in breast cancer cell lines and primary tumors.
Bilanges B; Varrault A; Basyuk E; Rodriguez C; Mazumdar A; Pantaloni C; Bockaert J; Theillet C; Spengler D; Journot L
Oncogene; 1999 Jul; 18(27):3979-88. PubMed ID: 10435621
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor gene ZAC/PLAGL1: altered expression and loss of the nonimprinted allele in pheochromocytomas.
Jarmalaite S; Laurinaviciene A; Tverkuviene J; Kalinauskaite N; Petroska D; Böhling T; Husgafvel-Pursiainen K
Cancer Genet; 2011 Jul; 204(7):398-404. PubMed ID: 21872827
[TBL] [Abstract][Full Text] [Related]
6. ZAC, LIT1 (KCNQ1OT1) and p57KIP2 (CDKN1C) are in an imprinted gene network that may play a role in Beckwith-Wiedemann syndrome.
Arima T; Kamikihara T; Hayashida T; Kato K; Inoue T; Shirayoshi Y; Oshimura M; Soejima H; Mukai T; Wake N
Nucleic Acids Res; 2005; 33(8):2650-60. PubMed ID: 15888726
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the methylation-sensitive promoter of the imprinted ZAC gene supports its role in transient neonatal diabetes mellitus.
Varrault A; Bilanges B; Mackay DJ; Basyuk E; Ahr B; Fernandez C; Robinson DO; Bockaert J; Journot L
J Biol Chem; 2001 Jun; 276(22):18653-6. PubMed ID: 11297535
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific imprinting of the ZAC/PLAGL1 tumour suppressor gene results from variable utilization of monoallelic and biallelic promoters.
Valleley EM; Cordery SF; Bonthron DT
Hum Mol Genet; 2007 Apr; 16(8):972-81. PubMed ID: 17341487
[TBL] [Abstract][Full Text] [Related]
9. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
[TBL] [Abstract][Full Text] [Related]
10. The candidate tumor suppressor gene ZAC is involved in keratinocyte differentiation and its expression is lost in basal cell carcinomas.
Basyuk E; Coulon V; Le Digarcher A; Coisy-Quivy M; Moles JP; Gandarillas A; Journot L
Mol Cancer Res; 2005 Sep; 3(9):483-92. PubMed ID: 16179495
[TBL] [Abstract][Full Text] [Related]
11. The cell cycle control gene ZAC/PLAGL1 is imprinted--a strong candidate gene for transient neonatal diabetes.
Kamiya M; Judson H; Okazaki Y; Kusakabe M; Muramatsu M; Takada S; Takagi N; Arima T; Wake N; Kamimura K; Satomura K; Hermann R; Bonthron DT; Hayashizaki Y
Hum Mol Genet; 2000 Feb; 9(3):453-60. PubMed ID: 10655556
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
13. LOT1 (PLAGL1/ZAC1), the candidate tumor suppressor gene at chromosome 6q24-25, is epigenetically regulated in cancer.
Abdollahi A; Pisarcik D; Roberts D; Weinstein J; Cairns P; Hamilton TC
J Biol Chem; 2003 Feb; 278(8):6041-9. PubMed ID: 12473647
[TBL] [Abstract][Full Text] [Related]
14. The human HYMAI/PLAGL1 differentially methylated region acts as an imprint control region in mice.
Arima T; Yamasaki K; John RM; Kato K; Sakumi K; Nakabeppu Y; Wake N; Kono T
Genomics; 2006 Nov; 88(5):650-8. PubMed ID: 16928428
[TBL] [Abstract][Full Text] [Related]
15. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines.
Dowdy SC; Gostout BS; Shridhar V; Wu X; Smith DI; Podratz KC; Jiang SW
Gynecol Oncol; 2005 Oct; 99(1):126-34. PubMed ID: 16023706
[TBL] [Abstract][Full Text] [Related]
16. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas.
Pagotto U; Arzberger T; Theodoropoulou M; Grübler Y; Pantaloni C; Saeger W; Losa M; Journot L; Stalla GK; Spengler D
Cancer Res; 2000 Dec; 60(24):6794-9. PubMed ID: 11156367
[TBL] [Abstract][Full Text] [Related]
17. Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer.
Soejima H; Nakagawachi T; Zhao W; Higashimoto K; Urano T; Matsukura S; Kitajima Y; Takeuchi M; Nakayama M; Oshimura M; Miyazaki K; Joh K; Mukai T
Oncogene; 2004 May; 23(25):4380-8. PubMed ID: 15007390
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic alteration at the DLK1-GTL2 imprinted domain in human neoplasia: analysis of neuroblastoma, phaeochromocytoma and Wilms' tumour.
Astuti D; Latif F; Wagner K; Gentle D; Cooper WN; Catchpoole D; Grundy R; Ferguson-Smith AC; Maher ER
Br J Cancer; 2005 Apr; 92(8):1574-80. PubMed ID: 15798773
[TBL] [Abstract][Full Text] [Related]
20. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
Cvetkovic D; Pisarcik D; Lee C; Hamilton TC; Abdollahi A
Gynecol Oncol; 2004 Dec; 95(3):449-55. PubMed ID: 15581945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
